155 related articles for article (PubMed ID: 12946064)
1. Reviving protease inhibitors: new data and more options.
Murphy RL
J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S43-52; quiz S53, S55-6. PubMed ID: 12946064
[No Abstract] [Full Text] [Related]
2. Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
Khanlou H; Bhatti L; Farthing C
J Acquir Immune Defic Syndr; 2006 Jan; 41(1):124-5. PubMed ID: 16340485
[No Abstract] [Full Text] [Related]
3. An update and review of antiretroviral therapy.
Piacenti FJ
Pharmacotherapy; 2006 Aug; 26(8):1111-33. PubMed ID: 16863488
[TBL] [Abstract][Full Text] [Related]
4. HIV protease inhibitors: recent clinical trials and recommendations on use.
Fernández-Montero JV; Barreiro P; Soriano V
Expert Opin Pharmacother; 2009 Jul; 10(10):1615-29. PubMed ID: 19527188
[TBL] [Abstract][Full Text] [Related]
5. Peptidomimetic inhibitors of HIV protease.
Randolph JT; DeGoey DA
Curr Top Med Chem; 2004; 4(10):1079-95. PubMed ID: 15193140
[TBL] [Abstract][Full Text] [Related]
6. Does atazanavir cause lipodystrophy?
Gazzard BG; Moyle G
J HIV Ther; 2004 May; 9(2):41-4. PubMed ID: 15238875
[TBL] [Abstract][Full Text] [Related]
7. [Two year use of Telzir: what are the perspectives?].
Med Mal Infect; 2007 Mar; 37(3):181-6. PubMed ID: 17552082
[No Abstract] [Full Text] [Related]
8. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
[No Abstract] [Full Text] [Related]
9. Initial therapy for human immunodeficiency virus: broadening the options.
Sension M
HIV Clin Trials; 2004; 5(2):99-111. PubMed ID: 15116286
[TBL] [Abstract][Full Text] [Related]
10. Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir.
Haerter G; Manfras BJ; Mueller M; Kern P; Trein A
AIDS; 2004 Apr; 18(6):952-5. PubMed ID: 15060446
[No Abstract] [Full Text] [Related]
11. Protease inhibitors: the current status.
Dauer B
J HIV Ther; 2005 Dec; 10(4):72-4. PubMed ID: 16519246
[No Abstract] [Full Text] [Related]
12. Boosting HIV treatment options: good news, new challenges.
Cahn P; Sued O
J Infect Dis; 2013 Jul; 208(1):4-6. PubMed ID: 23532095
[No Abstract] [Full Text] [Related]
13. Meeting report. Report from ICAAC.
Sax PE
AIDS Clin Care; 2006 Dec; 18(12):111-2. PubMed ID: 17228446
[No Abstract] [Full Text] [Related]
14. Atazanavir: clinical use.
Bartlett JG
Hopkins HIV Rep; 2003 Jul; 15(4):3-4. PubMed ID: 14696561
[No Abstract] [Full Text] [Related]
15. Atazanavir: improving the HIV protease inhibitor class.
Becker S
Expert Rev Anti Infect Ther; 2003 Oct; 1(3):403-13. PubMed ID: 15482137
[TBL] [Abstract][Full Text] [Related]
16. Changes in kidney function in patients with suppressed HIV RNA who substitute their protease inhibitor with atazanavir/ritonavir.
Hamzah L; Campbell L; Wandolo E; Engler B; Cheserem E; Naftalin C; Taylor C; Post FA
AIDS; 2015 Jan; 29(3):392-4. PubMed ID: 25686688
[No Abstract] [Full Text] [Related]
17. HIV-associated lipodystrophy: impact of antiretroviral therapy.
Guaraldi G; Stentarelli C; Zona S; Santoro A
Drugs; 2013 Sep; 73(13):1431-50. PubMed ID: 24002702
[TBL] [Abstract][Full Text] [Related]
18. Tipranavir in the protease inhibitors arena.
Vergani B; Rusconi S
Drugs R D; 2011 Dec; 11(4):291-3. PubMed ID: 22133386
[No Abstract] [Full Text] [Related]
19. Some existing drugs work on resistant HIV.
AIDS Alert; 2000 Jan; 15(1):10-2. PubMed ID: 11366357
[TBL] [Abstract][Full Text] [Related]
20. Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
Tomasselli AG; Heinrikson RL
Biochim Biophys Acta; 2000 Mar; 1477(1-2):189-214. PubMed ID: 10708858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
